About Pharmacyclics (NASDAQ:PCYC)
Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity1.93%
Return on Assets1.52%
Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions
What is Pharmacyclics' stock symbol?
Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."
How were Pharmacyclics' earnings last quarter?
Pharmacyclics, Inc. (NASDAQ:PCYC) posted its earnings results on Friday, May, 1st. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to the consensus estimate of $226.27 million. Pharmacyclics had a net margin of 2.02% and a return on equity of 1.93%. View Pharmacyclics' Earnings History.
Who are some of Pharmacyclics' key competitors?
Some companies that are related to Pharmacyclics include Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Intel (INTC), Cisco Systems (CSCO), Comcast (CMCSA), PepsiCo (PEP), Netflix (NFLX), Nvidia (NVDA), Amgen (AMGN), Adobe Systems (ADBE), Booking (BKNG), Texas Instruments (TXN), Broadcom (AVGO) and Gilead Sciences (GILD).
Has Pharmacyclics been receiving favorable news coverage?
Media stories about PCYC stock have been trending somewhat positive on Friday, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pharmacyclics earned a news sentiment score of 0.04 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Pharmacyclics?
Shares of PCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Pharmacyclics?
Pharmacyclics' mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.
MarketBeat Community Rating for Pharmacyclics (PCYC)MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe PCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pharmacyclics (NASDAQ:PCYC) Analyst Ratings History
(Data available from 4/20/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Pharmacyclics (NASDAQ:PCYC) Earnings History and Estimates Chart
Pharmacyclics (NASDAQ PCYC) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2015||Q115||$0.11||$0.13||$226.27 million||$206.00 million||View||N/A|
|2/18/2015||Q414||$0.76||$0.96||$267.50 million||$290.00 million||View||N/A|
|11/4/2014||Q314||$0.37||$0.69||$201.50 million||$207.10 million||View||N/A|
|7/31/2014||Q214||($0.23)||($0.26)||$95.88 million||$113.00 million||View||N/A|
|5/2/2014||Q114||$0.17||$0.40||$105.38 million||$119.40 million||View||N/A|
|2/20/2014||Q413||$0.67||$0.95||$85.69 million||$123.60 million||View||N/A|
|11/7/2013||Q3 2013||$0.31||$0.55||$68.19 million||$79.09 million||View||N/A|
|7/31/2013||Q2 2013||($0.07)||$0.26||$52.00 million||$54.70 million||View||N/A|
|5/1/2013||Q3 2013||($0.03)||($0.40)||$2.84 million||View||N/A|
|2/14/2013||Q2 2013||$0.29||$0.62||$45.74 million||$57.96 million||View||N/A|
|11/5/2012||Q113||$0.75||$1.14||$87.64 million||$102.70 million||View||N/A|
|9/5/2012||Q412||($0.27)||($0.22)||$3.49 million||$2.10 million||View||N/A|
Pharmacyclics (NASDAQ:PCYC) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Pharmacyclics (NASDAQ PCYC) Insider Trading and Institutional Ownership History
Pharmacyclics (NASDAQ PCYC) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/13/2015||Manmeet Singh Soni||CFO||Sell||27,514||$254.24||$6,995,159.36|| |
|3/12/2015||Heow Tan||Insider||Sell||1,000||$254.51||$254,510.00|| |
|11/12/2014||Maky Zanganeh||COO||Sell||30,482||$134.69||$4,105,620.58|| |
|11/10/2014||Maky Zanganeh||COO||Sell||23,000||$133.83||$3,078,090.00|| |
|11/10/2014||Richard B Love||General Counsel||Sell||1,500||$133.87||$200,805.00|| |
|11/7/2014||Maky Zanganeh||COO||Sell||1,551||$135.01||$209,400.51|| |
|11/7/2014||Maria Fardis||Insider||Sell||5,000||$134.50||$672,500.00|| |
|9/4/2014||Maky Zanganeh||COO||Sell||12,000||$121.75||$1,461,000.00|| |
|8/27/2014||Richard B Love||General Counsel||Sell||1,500||$124.00||$186,000.00|| |
|8/13/2014||Heow Tan||Insider||Sell||10,000||$123.58||$1,235,800.00|| |
|8/7/2014||Jesse Mcgreivy||Insider||Sell||34,062||$120.92||$4,118,777.04|| |
|3/5/2014||Boultbee Paula Sjovall||EVP||Sell||20,000||$138.22||$2,764,400.00||1,739|| |
|3/5/2014||Gregory Hemmi||VP||Sell||15,000||$140.00||$2,100,000.00||38,004|| |
|3/5/2014||Jesse Mcgreivy||Insider||Sell||6,563||$139.66||$916,588.58|| |
|3/4/2014||Betty Chang||VP||Sell||17,500||$137.97||$2,414,475.00||3,754|| |
|2/27/2014||Den Broek Richard Van||Director||Sell||78,835||$146.63||$11,559,576.05|| |
|12/19/2013||Heow Tan||Insider||Sell||5,000||$100.87||$504,350.00||169|| |
|12/18/2013||Gregory Hemmi||VP||Sell||20,000||$100.52||$2,010,400.00||25,004|| |
|12/16/2013||Rainer Erdtmann||VP||Sell||54,000||$107.77||$5,819,580.00||5,497|| |
|6/6/2013||Scott T Shearer||VP||Sell||18,750||$85.17||$1,596,937.50|| |
|5/31/2013||Heow Tan||Insider||Sell||5,237||$91.84||$480,966.08|| |
|5/31/2013||Jesse Mcgreivy||VP||Sell||14,479||$91.13||$1,319,471.27|| |
|2/5/2013||David J Loury||Insider||Sell||20,000||$70.58||$1,411,600.00|| |
|12/28/2012||Den Broek Richard Van||Director||Sell||30,285||$57.99||$1,756,227.15|| |
|12/27/2012||Gregory Hemmi||VP||Sell||13,000||$59.20||$769,600.00|| |
Pharmacyclics (NASDAQ PCYC) News Headlines
Pharmacyclics (NASDAQ:PCYC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pharmacyclics (NASDAQ:PCYC) Income Statement, Balance Sheet and Cash Flow Statement
Pharmacyclics (NASDAQ PCYC) Stock Chart for Friday, April, 20, 2018